In our study of 61 newly diagnosed CLL patients, which included 39 patients with CD38-positive leukemic cells, we demonstrated the presence of the chemokine receptors CCR1 and CCR2 on the circulating CD19+CD5+ and CD19+CD5− lymphocytes in the CD38-positive patients. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.